-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Proteasome inhibitors are effective against Waldenström's macroglobulinemia (WM), but require intravenous administration and are associated with polyneuropathy
.
The study investigated the efficacy and toxicity of the less neurotoxic oral proteasome inhibitor Ixazomib combined with rituximab in the treatment of patients with recurrent WM
This is a multicenter Phase 1/2 clinical trial that treats WM patients with ixazomib, rituximab, and dexamethasone (IRD)
.
The induction program includes 8 courses of IRD, of which rituximab is given from the third course of treatment, followed by rituximab for maintenance
A total of 59 patients (average 69 years; range 46-91 years) were recruited
.
The median number of previous treatments was 2 (range 1-17); 70% of patients had a medium to high WH-IPSS (WH International Prognostic Scoring System) score
Mean hemoglobin and hematocrit before eight cycles of treatment-induced immune changes in levels of immunoglobulin M
8 courses before the course of treatment-induced mean hemoglobin and hematocrit immune changes immunoglobulin M levels of immunityThe median duration of remission was 36 months
.
After induction therapy, the average hematocrit of the tested patients increased significantly (0.
After induction therapy, the average hematocrit of the test patient increased significantly.
PFS and OS in intention-to-treat analysis
PFS and OS in intention-to-treat analysisThe median time before the first remission was 4 months
.
The median progression-free survival and overall survival were not reached
After a median follow-up of 24 months (range 7.
Infect
In summary, the combined application of IRD has shown good efficacy and controllable toxicity in patients with relapsed or refractory WM
The combined application of IRD has shown good efficacy and controllable toxicity in patients with relapsed or refractory WM.
Original source:
Marie José Kersten, et al.
Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I / II HOVON124 / ECWM-R2 Study in this message
